---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-016790"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:40:53.188489+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Q4 GAAP loss $1.50/share; adj EPS $0.32; 2024 EBITDA guidance $200-220M

## Summary
- GAAP diluted loss from continuing ops $1.50 vs income $0.29 a year ago; $168.3M non-cash impairment.
- Adj EPS $0.32 (down from $0.47); net revenue $496M (-3.4% YoY); same-unit revenue -1.5%.
- Q4 adjusted EBITDA $50.8M (vs $66.5M); full-year adj EBITDA $200.4M (vs $241M).
- Preliminary 2024 adj EBITDA guidance $200-220M, roughly flat to down from 2023.
- Net AR $272.3M; total debt $628M; no revolver borrowings; cash from ops $72.1M.

## SEC filing metadata
- accession: 0000950170-24-016790
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/md-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-016790
- JSON: https://secwatch.observer/filing/0000950170-24-016790.json
- Plain text: https://secwatch.observer/filing/0000950170-24-016790.txt

## Key facts
- Earnings Releases
  Pediatrix Medical Group, Inc. reported the year ended December 31, 2023 results: revenue $1.99 billion.
  - Period: the year ended December 31, 2023
  - Revenue: $1.99 billion
  - Result: reported results
  source text: For the year ended December 31, 2023, Pediatrix generated revenue from continuing operations of $1.99 billion, compared to $1.97 billion for the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm
- Earnings Releases
  Pediatrix Medical Group, Inc. reported the three months ended December 31, 2023 results: revenue $496 million, net income Loss from continuing operations of $124 million, EPS loss from continuing operations of $1.50 per diluted share.
  - Period: the three months ended December 31, 2023
  - Revenue: $496 million
  - Net income: Loss from continuing operations of $124 million
  - EPS: loss from continuing operations of $1.50 per diluted share
  - Result: reported results
  source text: For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $496 million; • Loss from continuing operations of $124 million; and • Adjusted EBITDA of $51 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.